WellPoint Cancer Drug Pathways Program Aims To Save 4% In Annual Costs
This article was originally published in The Pink Sheet Daily
When it is fully operational in all 14 WellPoint states, more than 21 million members will be eligible for the initiative to standardize cancer prescribing and lower drug costs.
You may also be interested in...
With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.
Over the last two years, UnitedHealthcare and Aetna have launched cancer pathway programs with the overall goals of standardizing and improving care and lowering cost. Drug therapy is a key focus.
A new study highlights a subset of high-cost drugs in Medicaid for which legal and policy tools may be available to manage spending growth.